U.S. markets closed

Brainstorm Cell Therapeutics Inc. (BCLI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.9900-0.1900 (-3.67%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.1800
Open5.1600
Bid4.9600 x 2900
Ask5.0900 x 1100
Day's Range4.8500 - 5.4400
52 Week Range3.6300 - 17.9500
Volume2,030,629
Avg. Volume1,080,366
Market Cap157.522M
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)-1.0180
Earnings DateFeb 16, 2021 - Feb 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • BrainStorm to present NurOwn® Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
    PR Newswire

    BrainStorm to present NurOwn® Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that results from the Company's placebo controlled, randomized, double-blind Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for ALS will be presented as an oral presentation at the 31st International Symposium on ALS/MND to be held as a virtual symposium Dec 9-11th, 2020. In addition, Brainstorm will present the clinical experience with NurOwn outpatient administration during the phase 3 clinical trial in the poster session.

  • Zacks Small Cap Research

    BCLI: Phase 3 ALS Trial Does Not Meet Primary Endpoint…

    By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Phase 3 ALS Trial Does Not Meet Primary Endpoint On November 17, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced topline results from the company’s Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS). The trial did not reach statistical significance for the

  • Why BrainStorm Cell Therapeutics Stock Imploded Today
    Motley Fool

    Why BrainStorm Cell Therapeutics Stock Imploded Today

    Traders are selling off shares of the clinical-stage biotech company following the release of negative top-line results from a phase 3 clinical trial for its leading candidate treatment. BrainStorm Cell Therapeutics has been developing NurOwn as a potential treatment for amyotrophic lateral sclerosis (ALS), a nervous system disease that causes a progressive loss of muscle control and function. With that said, it was generally well-tolerated from a safety standpoint, and did demonstrate some encouraging results; BrainStorm Cell Therapeutics says it has not given up on NurOwn yet.